Blog
Bruce Power to support Brain Tumour Foundation of Canada, Pediatric Oncology Group of Ontario through Ontario Hockey League partnership for 2019-2020 season
TIVERTON, ON – November 1, 2019 – Bruce Power will continue its sponsorship agreement with the Ontario Hockey League (OHL) for the 2019-20 season by highlighting its support of Brain Tumour Foundation of Canada and the Pediatric Oncology Group of Ontario (POGO).
Through its partnership, Bruce Power will sponsor games in 16 OHL communities during the regular season to raise awareness around Brain Tumour Foundation of Canada and POGO. Both organizations will have an opportunity – through splitting the 16 games – to set up information/awareness kiosks inside the arenas on their respective game nights while the teams will promote POGO, Brain Tumour Foundation of Canada and Bruce Power on its social media channels and through their in-game promotions.
“Since becoming a partner of the Ontario Hockey League in 2017, we’ve been able to work with the league and teams on charitable initiatives that help raise awareness around the important work being done by the Brain Tumour Foundation of Canada and POGO on behalf of cancer patients and their families across Ontario,” said James Scongack, Executive Vice-President, Corporate Affairs and Operational Services. “Supporting these two organizations is an extension of the work our employees are doing in providing the world with medical isotopes that are used every day in the diagnosis and treatment of cancer.”
OHL Commissioner David Branch says the league and its teams share Bruce Power’s commitment to making their communities better places to live through charitable programs.
“The Ontario Hockey League greatly appreciates the work being done by our partners at Bruce Power and their support of these two great organizations that help countless people in our communities,” Branch said. “Cancer impacts everyone and this charitable effort will raise a great deal of awareness league-wide.”
Brain Tumour Foundation of Canada didn’t hesitate to participate in the Bruce Power-sponsored games, having seen an increase in awareness around the organization and its programs with its presence at OHL games last season.
“For 37 years now, Brain Tumour Foundation of Canada has funded brain tumour research while providing the brain tumour community with emotional support, access to accurate information and a connection to others facing this challenging disease,” said Susan Marshall, Chief Executive Officer, Brain Tumour Foundation of Canada. “We’re grateful to Bruce Power, the Ontario Hockey League and its clubs for allowing us to tell our story to hockey fans throughout the province.”
Like Brain Tumour Foundation of Canada, POGO works in several OHL communities and is taking advantage of the opportunity to tell its story to major junior hockey fans.
Each year in Ontario, there are over 4,000 families with a child in cancer treatment or follow-up care. More than 86 per cent of children diagnosed with cancer will survive. Nearly 60 per cent of these survivors will experience complications either due to the disease itself, complex surgical procedures or the rigorous rounds of radiation and chemotherapy they were given during treatment. POGO champions childhood cancer care for now – for life.
“Creative collaboration allows us to work towards a collective goal, and POGO is proud to partner with Bruce Power and the OHL to raise awareness of Childhood Cancer across Ontario,” said Lynn Wilson, Chief Development Officer at POGO.
The Bruce Power-sponsored games begin this evening in Kingston and Kitchener and continue through February 5.
- Kingston Frontenacs – November 1, 2019 (Brain Tumour Foundation of Canada)
- Kitchener Rangers – November 1, 2019 (POGO)
- Mississauga Steelheads – November 17, 2019 (POGO)
- Sudbury Wolves – November 17, 2019 (POGO)
- Oshawa Generals- November 22, 2019 (POGO)
- Barrie Colts – November 23, 2019 (Brain Tumour Foundation of Canada)
- Peterborough Petes – November 23, 2019 (POGO)
- London Knights – December 28, 2019 (Brain Tumour Foundation of Canada)
- Sarnia Sting – January 3, 2020 (Brain Tumour Foundation of Canada)
- Hamilton Bulldogs – January 4, 2020 (POGO)
- Niagara IceDogs – January 9, 2020 (POGO)
- Ottawa 67’s – January 12, 2020 (POGO)
- Guelph Storm – January 17, 2020 (Brain Tumour Foundation of Canada)
- Windsor Spitfires – January 19, 2020 (Brain Tumour Foundation of Canada)
- North Bay Battalion – January 30, 2020 (Brain Tumour Foundation of Canada)
- Sault Ste. Marie Greyhounds – February 5, 2020 (Brain Tumour Foundation of Canada)
About Bruce Power
Formed in 2001, Bruce Power is an electricity company based in Bruce County, Ontario. We are powered by our people. Our 4,100 employees are the foundation of our accomplishments and are proud of the role they play in safely delivering clean, reliable, low-cost nuclear power to families and businesses across the province. Bruce Power is also a significant source of Cobalt-60, a radioisotope used for the sterilization of medical equipment around the world as well as a specialized form of cancer treatment called the Gamma Knife. Learn more at www.brucepower.com and follow us on Facebook, Twitter, LinkedIn, Instagram and YouTube.
For more information, contact:
John Peevers – Director, Corporate Communications – 519-361-6583 – john.peevers@brucepower.com
About the OHL
The Ontario Hockey League is a proud member of the Canadian Hockey League which is the world’s largest development hockey league with 60 teams in nine Canadian provinces and five American states. In addition to the OHL, the CHL is made up of the Quebec Major Junior Hockey League and the Western Hockey League. Last season, more than nine million fans attended CHL games in the regular season, playoffs and at the MasterCard Memorial Cup. The CHL supplies more players to the National Hockey League than any other league. Last season 527 graduates attended Canadian Universities on scholarships from CHL teams.
For more information, contact:
Josh Sweetland – Director, Communications – 416-299-8700 – jsweetland@chl.ca
About Brain Tumour Foundation of Canada
Brain Tumour Foundation of Canada is the only national charity offering information and support to patients affected by any kind of brain tumour – be it cancerous, non-malignant or metastases. The organization funds ground-breaking research across North America and, since 1982, has dedicated over $7.2 million to finding a cure and improving treatment for brain tumour survivors. Brain Tumour Foundation of Canada is funded solely through generous contributions from individuals, corporations, organizations, employee groups and special events. Learn more at Brain Tumour Foundation of Canada’s website at www.BrainTumour.ca.
For more information, contact:
Susan Marshall – Chief Executive Officer, Brain Tumour Foundation of Canada –smarshall@braintumour.ca – 1-800-265-5106 ext. 222
About the Pediatric Oncology Group of Ontario
In 1983, a group of passionate and visionary pediatric oncologists founded the Pediatric Oncology Group of Ontario (POGO). Today, inspired by the children and families whose lives we strive to improve, we champion childhood cancer care on behalf of the childhood cancer community. POGO is the official source of advice on childhood cancer to the Ministry of Health; a trusted source of information among colleagues, parents, survivors and the public; and the longstanding leader of a collaboration among the five academic pediatric oncology programs and other stakeholders, which has resulted in a highly integrated childhood cancer system. Learn more at www.pogo.ca and follow us on Facebook, Twitter, LinkedIn, Instagram and YouTube.
For more information, contact:
Jacqui DeBique – Communications Manager – 416-592-1232, ext. 266 – jdebique@pogo.ca
Bruce Power Expresses Support for POGO’s Survivorship Initiatives
L to R: Dr. Mark Greenberg, Senior Clincal Lead, Strategic Initiatives and Founder, POGO; Mike Rencheck, President & CEO, Bruce Power; Bill Walker, MPP, Associate Minister of Energy; Jill Ross, CEO, POGO; James Scongack, Executive Vice President, Corporate Affairs & Operational Services, Bruce Power; Dr. David Hodgson, Medical Director, POGO; Dirk Noyahr, childhood cancer survivor and client in POGO’s school and work counselling program
Tiverton, ON (October 30, 2019) — Bruce Power announced today that it is fully committed to supporting the Pediatric Oncology Group of Ontario’s initiatives to provide children with cancer, their families, and survivors of childhood cancer, with access to ongoing treatment, care and financial support.
The announcement, made at the MaRS Centre in Toronto, reinforces a $300,000 commitment made by Bruce Power to POGO on February 15 – International Childhood Cancer Day. Bruce Power, a leader in the production of medical isotopes that are used around the world to improve people’s lives, will provide the funding over the next five years as a key element of the company’s Community Investment and Sponsorship Program.
“Our commitment to the people of Ontario crosses many paths,” said Mike Rencheck, Bruce Power President and CEO. “We provide 30 per cent of the province’s electricity at 30 per cent less than the cost to generate residential power. We inject $4 billion into Ontario’s economy every year, and we contribute $2 million annually to grassroots initiatives, events and organizations that improve the lives of children, adults, Indigenous peoples and military veterans.
“The continuing efforts around our production of medical isotopes are heavily focused on working with the medical community and other partners to find new ways for treating cancer. We share the values of POGO in providing state-of-the-art care to those afflicted with cancer in their childhood years, and doing what it can for families dealing with this life-changing diagnosis.”
One program supported by the Bruce Power funding is POGO’s school and work counselling service for childhood cancer survivors (SAVTI). POGO launched this program in 2002 to address a significant gap in survivor care, helping survivors, aged 16 plus, with neurocognitive challenges receive the necessary support to set and attain realistic educational and employment goals. POGO provides one-on-one counselling tailored to a student’s medical past and subsequent cognitive profile to help them bridge the gap between high school and whatever comes next for that student. POGO counsellors, specialists in their field, support clients in London, Hamilton, Toronto, Ottawa, Kingston and the surrounding areas. Together with neuropsychologists, they also help young people identify and access the accommodations they need, connect to resources in the community, and receive guidance to empower them to become self-advocates at school and at work. POGO counsellors provided services to over 400 cancer survivors last year.
“Bruce Power’s multi-year commitment provides stable funding that will allow us to plan long-term for initiatives that support childhood cancer survivors, as well as Ontario families with children in cancer treatment,” said Jill Ross, POGO’s CEO. “Our work with community partners like Bruce Power, who share our commitment to helping people deal with cancer, plays an important role in ensuring a high-quality, safe and coordinated system of care that addresses both their physical and emotional well-being.”
“In addition to being the backbone of our province’s energy system, Bruce Power is now also an important partner in Ontario’s health care system, producing life-saving medical isotopes and providing financial and other supports to help fight childhood cancer,” said Bill Walker, MPP, Bruce-Grey-Owen Sound and Associate Minister of Energy. “I commend your commitment and look forward to the great work from your new partnership with the Pediatric Oncology Group of Ontario.”
About Bruce Power
Formed in 2001, Bruce Power is an electricity company based in Bruce County, Ontario. We are powered by our people. Our 4,100 employees are the foundation of our accomplishments and are proud of the role they play in safely delivering clean, reliable, low-cost nuclear power to families and businesses across the province. Bruce Power is also a significant source of Cobalt-60, a radioisotope used for the sterilization of medical equipment around the world as well as a specialized form of cancer treatment called the Gamma Knife. Learn more at www.brucepower.com and follow us on Facebook, Twitter, LinkedIn, Instagram and YouTube.
About the Pediatric Oncology Group of Ontario
In 1983, a group of passionate and visionary pediatric oncologists founded the Pediatric Oncology Group of Ontario (POGO). Today, inspired by the children and families whose lives we strive to improve, we champion childhood cancer care on behalf of the childhood cancer community. POGO is the official source of advice on childhood cancer to the Ministry of Health; a trusted source of information among colleagues, parents, survivors and the public; and the longstanding leader of a collaboration among the five academic pediatric oncology programs and other stakeholders, which has resulted in a highly integrated childhood cancer system. Learn more at www.pogo.ca and follow us on Facebook, Twitter, LinkedIn, Instagram and YouTube
The Gordian Knot of Precision Medicine: Ethical Dilemmas and Psychosocial Impacts
Presentation Description:
Targeted drug therapies show promise for treating certain types of pediatric cancers. Yet, they also come with serious ethical and psychosocial implications that can have far-reaching impacts on patients, families and health professionals. Using a case-based approach with examples from Canada, Australia and the United States, this workshop will explore ethical and psychosocial implications of tumour sequencing, somatic and germline testing, and other aspects of precision medicine, and discuss potential strategies to address and mitigate them.
Speakers:
Conrad Fernandez, MD, FRCPC
Professor and Head, Pediatric Hematology/Oncology
IWK Health Centre
Senior Scientist, Beatrice Hunter Cancer Research Institute
Dalhousie University
Dr. Conrad Fernandez is Professor and Head of the Division of Pediatric Hematology Oncology at the IWK Health Centre and Dalhousie University. He is the founding Co-Chair of the Children’s Oncology Group (COG) Return of Research Results Committee and Vice Chair of the COG Bioethics Committee. He is the lead of the Ethics Node of the Terry Fox Research Institute PROFYLE Project. He is a member of the Panel on Research Ethics, which informs the research ethics policy of Canada, called the TriCouncil Policy Statement on Ethical Conduct for Research Involving Humans. He is a Senior Scientist and a Chair of the Research Committee for the Beatrice Hunter Cancer Research Institute at Dalhousie University. He is Chair of the COG Renal Tumors Committee and a member of the COG Voting Body Steering Committee.
Dr. Fernandez’s two research passions are the development of clinical trials for children with renal tumours and exploring the many ethical challenges encountered in considering the return of summary or individual research results to participants.
Steven Joffe, MD, MPH
University of Pennsylvania Perelman School of Medicine
Emanuel and Robert Hart Professor of Medical Ethics and Health Policy
Dr. Steven Joffe is the Emanuel and Robert Hart Professor of Medical Ethics and Health Policy at the University of Pennsylvania Perelman School of Medicine. He serves as Chief of the Division of Medical Ethics and directs two post-doctoral fellowships in bioethics and in the ethical, legal and social implications of genomics. He is also Professor of Pediatrics at Children’s Hospital of Philadelphia.
Dr. Joffe attended Harvard College, received his MD from the University of California at San Francisco (UCSF), and received his MPH from UC Berkeley. He trained in pediatrics at UCSF and in hematology/oncology at the Dana-Farber Cancer Institute and Boston Children’s Hospital.
Dr. Joffe’s clinical work is in pediatric stem cell transplantation. His research addresses the ethical challenges that arise in the conduct of clinical and translational investigation. He has been principal investigator of National Institutes of Health, Patient-Centred Outcomes Research Institute (NIH, PCORI) and foundation-funded studies that examine the roles and responsibilities of principal investigators in multi-centre trials, governance in learning healthcare systems, return of genetic results to research participants, and the integration of genomic sequencing technologies into cancer care. He is a member of the U.S. FDA’s Pediatrics Ethics Subcommittee and of the National Human Genome Research Institute’s Genomics and Society Working Group.
Claire Wakefield, BPsych(hons), MPH, PhD
Director Behavioural Sciences Unit
Sydney Children’s Hospital
Professor Claire Wakefield, registered psychologist, is Director of the Behavioural Sciences Unit at Sydney Children’s Hospital, Australia. She is a chief investigator on grants worth >$26M and has published >140 peer-reviewed articles. Professor Wakefield holds a prestigious NHMRC Career Development Fellowship, and a $2.7M program grant, and is Co-Director of the SPHERE Kids to Adults (K2A): Creating Healthy Futures Clinical Academic Group. She chairs the pediatrics committee for the International Psycho-Oncology Society and founded the first international early career group for professionals working in pediatric psycho-oncology. Professor Wakefield’s team has created and implemented evidence-based resources for bereaved families, parents of children with cancer, and adolescents and young adults with cancer, including 10 clinical decision aids, many of which are now endorsed and disseminated by NSW Health. With increased use of genetic testing and personalized medicine in pediatrics, her team is assessing the psychological impact of new genetic technologies on children and families and is exploring the ethical questions arising in this novel area of medicine. Her team leads the patient-reported outcomes study in the PRISM clinical trial, one of the largest personalized medicine trials for childhood cancer patients worldwide.
Beneath the Surface: The Psychosocial Impacts of Precision Medicine
VIEW THE PRESENTATION
Presentation Description:
Precision medicine represents arguably the most exciting advance in pediatric oncology in recent decades. Despite great hope for this new approach to making individualized treatment recommendations for children with cancer, there will likely be associated psychosocial challenges for all stakeholders involved, including patients, parents, clinicians and scientists. Precision medicine trials are very complex, meaning that patients’/parents’ understanding about their treatment options might be limited. Healthcare professionals might also find it difficult to manage the psychosocial impacts of precision medicine for their patients. This presentation summarises the key potential impacts of precision medicine for children with cancer, their families and the professionals who care for them. Professor Wakefield will present data from recent systematic reviews, a large-scale acceptability study, plus emerging prospective data from the first 100 families enrolled in the Australian PRISM precision medicine trial for children with high-risk cancer.
Speaker:
Claire Wakefield, BPsych(hons), MPH, PhD
Director, Behavioural Sciences Unit
Sydney Children’s Hospital
Professor Claire Wakefield, registered psychologist, is Director of the Behavioural Sciences Unit at Sydney Children’s Hospital, Australia. She is a chief investigator on grants worth >$26M and has published >140 peer-reviewed articles. Professor Wakefield holds a prestigious NHMRC Career Development Fellowship, and a $2.7M program grant, and is Co-Director of the SPHERE Kids to Adults (K2A): Creating Healthy Futures Clinical Academic Group. She chairs the pediatrics committee for the International Psycho-Oncology Society and founded the first international early career group for professionals working in pediatric psycho-oncology. Professor Wakefield’s team has created and implemented evidence-based resources for bereaved families, parents of children with cancer, and adolescents and young adults with cancer, including 10 clinical decision aids, many of which are now endorsed and disseminated by NSW Health. With increased use of genetic testing and personalized medicine in pediatrics, her team is assessing the psychological impact of new genetic technologies on children and families and is exploring the ethical questions arising in this novel area of medicine. Her team leads the patient-reported outcomes study in the PRISM clinical trial, one of the largest personalized medicine trials for childhood cancer patients worldwide.
POGO CEO Reflects on The Childhood Cancer Care Plan One Year After Launch
Jill Ross, POGO CEO
Q. Looking back on the past year, which accomplishments stand out for you?
The Childhood Cancer Care Plan was developed by over 200 clinical experts, providing care in clinics and at the bedside day in and day out, as well as parents and survivors, system planners and administrators. It has been wonderful to see many of these same individuals along with new participants readily volunteering their time, expertise and experiences to committees and activities that will drive action on the Plan’s goals.
That said, two other items that particularly stand out, are the launch of the newest POGO Satellite Clinic at Peterborough Regional Heath Centre in fall 2018, bringing care closer to home for patients and their families in that part of the province, and the publication of the latest, high-quality Ontario data in Childhood Cancer in Ontario 1986–2015: A Surveillance Report.
Q. The Plan identifies the need for Champions. Describe how Champions have come on board to help implement the Plan.
The Childhood Cancer Care Plan is a system plan. In addition to POGO, it will take the collaborative efforts of survivors, patients and families, clinical care providers of all types, government, donors and others to achieve its goals. An excellent example of this collaboration is POGO’s work on the Plan’s strategic objective to “promote effective and appropriate care for adolescents and young adults (AYA) treated in all settings.” Adolescents and young adults have unique care needs that require us to bring the best from the childhood and adult cancer care systems.
This year, Champions from across the province—clinical specialists from the POGO network and from Cancer Care Ontario’s adult cancer programs, and survivors of AYA cancer, with the support of the Ministry of Health—have joined forces to identify actions that can be taken to improve care.
Q. Specialized donor-funded support for families, research and survivors is a key driver of the Plan’s success. How has the contribution of donors contributed to moving the goals of the Plan forward?
One of the Plan’s five major goals is to optimize the physical health and emotional well-being of survivors of childhood cancer. Survivors have told us that they are in need of practical and informational resources to help them cope with life after a diagnosis of childhood cancer. With the generous support of an anonymous donor to launch a new initiative and continued funding from The W. Garfield Weston Foundation, POGO has been able to enhance our counselling service for adolescent survivors facing challenges completing school and finding work by introducing the Survivor to Survivor (S2S) Network. With the S2S Network, survivors gain practical skills, build their confidence and connect with others, as they create and deliver informational workshops on key issues for fellow survivors. Feedback from participants so far has been outstanding.
Check out S2S workshop topics and hear from
S2S facilitators about their experience
Donors to POGO also support important research aligned with the Plan’s goals.
Q. This is a provincial plan intended to deliver the best possible care for the best possible outcomes for families, young people with cancer, survivors. What tangible differences are already evident for this population?
The POGO network has been working effectively together to continuously improve the system since POGO created the first Provincial Pediatric Oncology Plan (the Plan’s former name) in the late 1980s. Ontario’s outcomes are among the best in the world. Overall survival from childhood cancer is at an all-time high of 86%.
For children facing a diagnosis of cancer, in alignment with the Plan’s goal of “equitable, appropriate and timely access to emerging and evolving oncology drugs, diagnostics and technologies,” POGO ensures pediatric cancer expertise informs new drug funding policies and continues to lead the process to enable access to the latest collaborative clinical research studies for Ontario’s children facing cancer. POGO’s Therapeutic and Technology Advisory Committee of experts from across the province is now in place to continually scan the new science for opportunities to enhance care in Ontario.
Work also continues to enhance long-term outcomes for survivors of childhood cancer. Most survivors need lifelong monitoring to ensure that the late effects of their disease and its treatment are managed in such a way as to ensure the best quality of life possible. Survivors need reliable access to high quality primary and specialty care but, too often, access to primary care is a challenge. POGO’s Integrated Provincial AfterCare Steering Committee, composed of clinical and survivor representatives, aims to connect each survivor with a primary care provider in their home community and to ensure that primary care providers and the cancer specialists work effectively together to provide optimal monitoring.
Q. When we look ahead one year from now, what are some immediate priorities arising from the Plan?
While our clinical outcomes in Ontario are excellent, there are other important outcomes that need concerted attention. In particular, we hear from the clinical team and parents alike that the Plan’s goal about “ensuring integrated psychosocial care,” and objectives to “enhance supportive care” and “meet educational and information needs” are particularly challenging.
POGO’s guidelines program ensures that Ontario has excellent, internationally recognized, evidence-based supportive care guidelines, but more needs to be done to ensure that the recommendations in those guidelines can be put into day-to-day practice. The benefit of guidelines is real; a US children’s hospital, for example, saw a significant decrease in patient vomiting after implementing the POGO guideline for prevention of chemotherapy-induced vomiting. POGO is committed to working with our partners to facilitate evidence-based guideline uptake.
While we made an excellent start this past year, we also have more work to do to meet the Plan’s goal of ensuring “the right data are available and being used to drive an effective childhood cancer system.” We are working with hospital partners to give them the data they need to monitor quality and do local planning, and in turn, contribute to strong province-wide planning. We will also be updating the POGO Surveillance Report this year, and we are working with data partners to improve the information available about AYA cancer.
Most importantly, we look forward to strengthening existing partnerships and developing new ones with organizations that can help advance the Plan’s important goals for childhood cancer patients, families and survivors.